Skip to main content

Table 1 WHO Trial Registration Data Set

From: Effectiveness and cost-effectiveness of telephone-based cognitive-behavioural therapy in primary care: study protocol of TIDe – telephone intervention for depression

Data category


Primary registry and trial identifying number NCT02667366

Date of registration in primary register

3 December 2015

Sources of monetary or material support

Gottfried and Julia Bangerter-Rhyner-Foundation (Bangerter-Stiftung) and Swiss Academy of Medical Sciences (Schweizerische Akademie der Medizinischen Wissenschaften, SAMW)

Primary sponsor(s)

Prof. Birgit Watzke, University of Zurich

Contact for public queries

M.Sc. Elisa Haller

Department of Clinical Psychology and Psychotherapy Research

Binzmühlestrasse 14/16, CH-8050 Zürich


Contact for scientific queries

Prof. Dr. Birgit Watzke

Department of Clinical Psychology and Psychotherapy Research Binzmühlestrasse 14/16, CH-8050 Zürich


Public title

Telephone-Intervention/Information for Depression (TIDe)

Scientific title

Effectiveness and cost-effectiveness of a telephone-based cognitive-behavioural therapy in primary care for mild to moderate depression

Countries of recruitment


Health condition(s) or problem(s) studied

Mild to moderate depression


Telephone-delivered short-term cognitive-behavioural therapy

Key inclusion and exclusion criteria

Inclusion criteria: Age ≥ 18 years, mild to moderate depression according to ICD-10, PHQ-9 > 5 and ≤15, able to fill in questionnaires, German language

Exclusion criteria: suicidality or suicidal tendency, currently or in last 3 months in psychotherapeutic treatment, chronic depression or dysthymia, severe depression, psychopharmacological medication that is not stable for 3 months prior to enrolment.

Study type

Randomised-controlled superiority trial

Date of first enrolment

January 2016

Target sample size


Recruitment status


Primary outcome(s)

Symptom severity at t2 (PHQ-9)

Key secondary outcomes

Symptom severity at t1 (PHQ-9),

Response defined as 50% reduction from t0 to t1,remission defined as <5 points in the PHQ-9 at t2 and t1, relapse defined as ≥5 points in the PHQ at t2 following remission at t1, cost-effectiveness